Compugen Presents Prediction Based Discovery Strategy At “Targets And ... TheStreet.com (press release) ... within the infrastructure and has resulted to date in multiple discoveries, such as the previously disclosed CGEN-928 with potential use for late stage, aggressive and drug resistant multiple myeloma and Rituximab resistant non-Hodgkin's lymphoma. |
